Earnings Feed
Start Free
Celldex Therapeutics, Inc.·4

Jun 29, 4:06 PM ET

PENNER HARRY JR 4

Research Summary

AI-generated summary

Updated

Celldex (CLDX) Director Harry Penner Receives 26,000-Share Option Award

What Happened

  • Harry Penner Jr., a director of Celldex Therapeutics (CLDX), was granted a derivative award of 26,000 shares on 2026-06-25. The grant is recorded at $0.00 in the Form 4 and is reported as an acquisition via a derivative instrument (an option).

Key Details

  • Transaction date: 2026-06-25; Form 4 filed: 2026-06-29.
  • Transaction type/code: A (grant/award or other acquisition); 26,000 derivative shares at $0.00.
  • Footnote: F1 clarifies this represents an option granted under Celldex’s 2021 Omnibus Equity Incentive Plan.
  • Shares owned after transaction: not specified in the filing.
  • Timeliness: filing date is 2026-06-29 (the Form 4 was filed within the normal two-business-day reporting window for most insider reports).

Context

  • This filing reflects an option grant (a compensation award), not a cash purchase of stock or an exercise/sale. Option grants are common director compensation and do not by themselves indicate an immediate buy or sell decision.